Zynex Tanks 23% As Demand Hit By Covid-19; Street Stays Bullish, , on October 13, 2020 at 6:38 am

Financial News
By
On October 13, 2020
In Financial News
Tags:

Shares in medical tech stock Zynex (ZYXI) plunged 23% in Monday’s trading after the company revealed lower-than-expected orders for the second and third quarter due to the fallout from Covid-19. However shares rose 3% in after-hours trading.As a result, ZYXI updated its previous revenue estimate for the third quarter of 2020 to between $20.0 and $20.5 million compared to the previous estimate of between $22.3 and $22.8 million. Third quarter Adjusted EBITDA is in-line with the previous estimate and is expected to come in between $2.3 and $2.8 million.Thomas Sandgaard, CEO of Zynex said: “Similar to most companies we have seen the impact of the COVID-19 pandemic, not only on the availability of physicians to prescribe our products but also on navigating employee and supply chain issues. Our order growth during this pandemic has been encouraging with 96% growth year over year and 87% sequentially but was slightly lower than what we originally projected for Q3.”Zynex’s full year 2020 revenue estimate now falls between $80 and $81 million, at the lower end of the previously announced range of $80 to $85 million. Meanwhile the revenue estimate is approximately 76% to 78% above last year’s full year revenue of $45.5 million.According to the company, 2020 full year estimated adjusted EBITDA will be $12.5 to $13.5 million. It says that the decrease for the full year versus the prior estimate of $15 to $18 million is primarily related to the accelerated hiring of sales reps which was aided by the increased number of available candidates related to COVID-19.“The acceleration of sales rep hiring is a positive for our future but with the effects of COVID-19 on our revenue, there is a near-term effect on profitability” the company stated. Indeed, Zynex expects to have 500 sales reps in the US by the end of 2020 and over 600 by the end of 2021 (up from 400 sales reps in early September).Shares in Zynex have exploded by over 90% year-to-date, and the stock scores a bullish Strong Buy Street consensus. That’s with four back-to-back buy ratings. Meanwhile the average analyst price target stands at $26 (74% upside potential).Following the news Piper Sandler analyst Matt O’Brien reiterated his ZYXI buy rating and $30 price target (97% upside potential).He called the results a “near-term bump in the road”, arguing that the long-term Zynex picture continues to look compelling. In particular he sees the aggressive sales rep hiring as a notable positive- and advises investors to use weakness as a buying opportunity. (See ZYXI stock analysis on TipRanks)Related News: Eli Lilly In Gates Foundation Supply Deal For Covid-19 Antibodies Opko’s BioReference Lab Begins Covid-19 Testing At NYC Schools J&J’s Tremfya Study Shows Improvement In Crohn’s Disease Patients More recent articles from Smarter Analyst: * Nestlé Completes Tender Offer For 84% Stake In Aimmune Therapeutics * New Oriental Rises On Solid Earnings Beat Despite Covid-Headwinds * Altimmune’s COVID-19 Vaccine Shows Positive Results; Street Sees 289% Upside * Sanofi, Regeneron’s Dupixent Significantly Reduces Children’s Asthma Attacks,

Zynex Tanks 23% As Demand Hit By Covid-19; Street Stays BullishShares in medical tech stock Zynex (ZYXI) plunged 23% in Monday’s trading after the company revealed lower-than-expected orders for the second and third quarter due to the fallout from Covid-19. However shares rose 3% in after-hours trading.As a result, ZYXI updated its previous revenue estimate for the third quarter of 2020 to between $20.0 and $20.5 million compared to the previous estimate of between $22.3 and $22.8 million. Third quarter Adjusted EBITDA is in-line with the previous estimate and is expected to come in between $2.3 and $2.8 million.Thomas Sandgaard, CEO of Zynex said: “Similar to most companies we have seen the impact of the COVID-19 pandemic, not only on the availability of physicians to prescribe our products but also on navigating employee and supply chain issues. Our order growth during this pandemic has been encouraging with 96% growth year over year and 87% sequentially but was slightly lower than what we originally projected for Q3.”Zynex’s full year 2020 revenue estimate now falls between $80 and $81 million, at the lower end of the previously announced range of $80 to $85 million. Meanwhile the revenue estimate is approximately 76% to 78% above last year’s full year revenue of $45.5 million.According to the company, 2020 full year estimated adjusted EBITDA will be $12.5 to $13.5 million. It says that the decrease for the full year versus the prior estimate of $15 to $18 million is primarily related to the accelerated hiring of sales reps which was aided by the increased number of available candidates related to COVID-19.“The acceleration of sales rep hiring is a positive for our future but with the effects of COVID-19 on our revenue, there is a near-term effect on profitability” the company stated. Indeed, Zynex expects to have 500 sales reps in the US by the end of 2020 and over 600 by the end of 2021 (up from 400 sales reps in early September).Shares in Zynex have exploded by over 90% year-to-date, and the stock scores a bullish Strong Buy Street consensus. That’s with four back-to-back buy ratings. Meanwhile the average analyst price target stands at $26 (74% upside potential).Following the news Piper Sandler analyst Matt O’Brien reiterated his ZYXI buy rating and $30 price target (97% upside potential).He called the results a “near-term bump in the road”, arguing that the long-term Zynex picture continues to look compelling. In particular he sees the aggressive sales rep hiring as a notable positive- and advises investors to use weakness as a buying opportunity. (See ZYXI stock analysis on TipRanks)Related News: Eli Lilly In Gates Foundation Supply Deal For Covid-19 Antibodies Opko’s BioReference Lab Begins Covid-19 Testing At NYC Schools J&J’s Tremfya Study Shows Improvement In Crohn’s Disease Patients More recent articles from Smarter Analyst: * Nestlé Completes Tender Offer For 84% Stake In Aimmune Therapeutics * New Oriental Rises On Solid Earnings Beat Despite Covid-Headwinds * Altimmune’s COVID-19 Vaccine Shows Positive Results; Street Sees 289% Upside * Sanofi, Regeneron’s Dupixent Significantly Reduces Children’s Asthma Attacks

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage